BACKGROUND: Negative symptoms of schizophrenia can be grouped in 2 dimensions: apathy and diminished expression. Increasing evidence suggests that negative symptoms are associated with altered neural activity of subcortical and cortical regions in the brain reward system. However, the neurobiological basis of the distinct symptom dimensions within negative symptoms is still poorly understood. The primary aim of our study was to examine the neural correlates of the negative symptom dimensions apathy and diminished expression during a reward processing task. METHODS: Patients with schizophrenia and healthy controls underwent event-related fMRI while performing a variant of the Monetary Incentive Delay Task. We assessed negative symptom dimensions using the Brief Negative Symptom Scale. RESULTS: We included 27 patients and 25 controls in our study. Both groups showed neural activation indicated by blood oxygen-level dependent signal in the ventral striatum during reward anticipation. Ventral striatal activation during reward anticipation showed a strong negative correlation with apathy. Importantly, this effect was not driven by cognitive ability, medication, depressive or positive symptoms. In contrast, no significant correlation with the diminished expression dimension was observed. LIMITATIONS: Although the results remain significant when controlling for chlorpromazine equivalents, we cannot fully exclude potential confounding effects of medication with atypical antipsychotics. CONCLUSION: The specific correlation of ventral striatal hypoactivation during reward anticipation with apathy demonstrates a differentiation of apathy and diminished expression on a neurobiological level and provides strong evidence for different pathophysiological mechanisms underlying these 2 negative symptom dimensions. Our findings contribute to a multilevel framework in which apathy and motivational impairment in patients with schizophrenia can be described on psychopathological, behavioural and neural levels.
BACKGROUND: Negative symptoms of schizophrenia can be grouped in 2 dimensions: apathy and diminished expression. Increasing evidence suggests that negative symptoms are associated with altered neural activity of subcortical and cortical regions in the brain reward system. However, the neurobiological basis of the distinct symptom dimensions within negative symptoms is still poorly understood. The primary aim of our study was to examine the neural correlates of the negative symptom dimensions apathy and diminished expression during a reward processing task. METHODS:Patients with schizophrenia and healthy controls underwent event-related fMRI while performing a variant of the Monetary Incentive Delay Task. We assessed negative symptom dimensions using the Brief Negative Symptom Scale. RESULTS: We included 27 patients and 25 controls in our study. Both groups showed neural activation indicated by blood oxygen-level dependent signal in the ventral striatum during reward anticipation. Ventral striatal activation during reward anticipation showed a strong negative correlation with apathy. Importantly, this effect was not driven by cognitive ability, medication, depressive or positive symptoms. In contrast, no significant correlation with the diminished expression dimension was observed. LIMITATIONS: Although the results remain significant when controlling for chlorpromazine equivalents, we cannot fully exclude potential confounding effects of medication with atypical antipsychotics. CONCLUSION: The specific correlation of ventral striatal hypoactivation during reward anticipation with apathy demonstrates a differentiation of apathy and diminished expression on a neurobiological level and provides strong evidence for different pathophysiological mechanisms underlying these 2 negative symptom dimensions. Our findings contribute to a multilevel framework in which apathy and motivational impairment in patients with schizophrenia can be described on psychopathological, behavioural and neural levels.
Authors: Theodore D Satterthwaite; Daniel H Wolf; James Loughead; Kosha Ruparel; Mark A Elliott; Hakon Hakonarson; Ruben C Gur; Raquel E Gur Journal: Neuroimage Date: 2012-01-02 Impact factor: 6.556
Authors: Matthias N Hartmann; Oliver M Hager; Anna V Reimann; Justin R Chumbley; Matthias Kirschner; Erich Seifritz; Philippe N Tobler; Stefan Kaiser Journal: Schizophr Bull Date: 2014-07-22 Impact factor: 9.306
Authors: Karoline Schneider; Lars Michels; Matthias N Hartmann-Riemer; Achim Burrer; Philippe N Tobler; Philipp Stämpfli; Matthias Kirschner; Erich Seifritz; Stefan Kaiser Journal: J Psychiatry Neurosci Date: 2019-03-01 Impact factor: 6.186
Authors: Robert M Roth; Matthew A Garlinghouse; Laura A Flashman; Nancy S Koven; J Cara Pendergrass; James C Ford; Thomas W McAllister; Andrew J Saykin Journal: J Neuropsychiatry Clin Neurosci Date: 2016-02-22 Impact factor: 2.198
Authors: Pan Lin; Xiaosheng Wang; Bei Zhang; Brian Kirkpatrick; Dost Öngür; James J Levitt; Jorge Jovicich; Shuqiao Yao; Xiang Wang Journal: Hum Brain Mapp Date: 2017-11-02 Impact factor: 5.038
Authors: Matthias Kirschner; Oliver M Hager; Larissa Muff; Martin Bischof; Matthias N Hartmann-Riemer; Agne Kluge; Benedikt Habermeyer; Erich Seifritz; Philippe N Tobler; Stefan Kaiser Journal: Schizophr Bull Date: 2018-01-13 Impact factor: 9.306
Authors: Fernando Caravaggio; Gagan Fervaha; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Shinichiro Nakajima; Wanna Mar; Philip Gerretsen; Julia Kim; M Mallar Chakravarty; Benoit Mulsant; Bruce Pollock; David Mamo; Gary Remington; Ariel Graff-Guerrero Journal: Int J Geriatr Psychiatry Date: 2017-11-07 Impact factor: 3.485
Authors: Sarah Trost; Esther K Diekhof; Holger Mohr; Henning Vieker; Bernd Krämer; Claudia Wolf; Maria Keil; Peter Dechent; Elisabeth B Binder; Oliver Gruber Journal: Neuropsychopharmacology Date: 2016-05-13 Impact factor: 7.853